<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39391514</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43.</ArticleTitle><Pagination><StartPage>e37928</StartPage><MedlinePgn>e37928</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e37928</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e37928</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The recent SARS-CoV-2 pandemic renewed interest toward other non-severe acute respiratory syndrome human coronaviruses. Among these, OC43 is a seasonal human coronavirus widely diffused in the population (90 % seroprevalence in adults) which is responsible for mild respiratory symptoms. As OC43 protective immunity is short lasting, we investigated whether humoral immunity to SARS-CoV-2, induced by vaccination or spontaneous infection, protects against OC43 re-infection at either systemic or mucosal level.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A neutralization assay was conducted against "wild type" SARS-CoV-2 lineage B.1 (EU) and OC43 in VeroE6 cell lines using plasma and saliva samples from 49 subjects who were never infected and received three BNT162b2 RNA vaccine doses (SARS-CoV-2-vaccinated: SV) and from 25 SARS-CoV-2-infected and vaccinated subjects (SIV). The assays were performed right before (T0), fifteen days (T1) and three months (T2) after the third dose administration (SV) or post-infection (SIV).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">After the third vaccination dose was administered, SARS-CoV-2-specific neutralizing activity (NA) significantly augmented in SV saliva (p &lt; 0.05) and plasma (p &lt; 0.0001); yet, this NA was not protective against OC43. Conversely, in SIV, at T1, natural infection significantly increased NA against both SARS-CoV-2 (p &lt; 0.01) and OC43 (p &lt; 0.05) at systemic as well as mucosal level; still, this cross-reactivity vanished at T2. Of note, NA against SARS-CoV-2 and OC43 was shown to be higher in SIV compared to SV in plasma and saliva, as well; though, statistically significant differences were evident only in the oral mucosa at T1 (p &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our findings show that SARS-CoV-2 spontaneous infection triggers a more comprehensive and cross-reactive immunity than vaccine-induced immunity, protecting against OC43 at the systemic and mucosal levels. These results support the development of a pan-coronavirus vaccine able to prompt cross-reactive immunity even against seasonal coronaviruses, which could have enormous economic and health benefits globally.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garziano</LastName><ForeName>Micaela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cano Fiestas</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vanetti</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strizzi</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murno</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clerici</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Don C. Gnocchi Foundation, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Foundation, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biasin</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Immunobiology, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cross-reactive immunity</Keyword><Keyword MajorTopicYN="N">Human coronaviruses</Keyword><Keyword MajorTopicYN="N">Mucosal immunity</Keyword><Keyword MajorTopicYN="N">OC43</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39391514</ArticleId><ArticleId IdType="pmc">PMC11466580</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e37928</ArticleId><ArticleId IdType="pii">S2405-8440(24)13959-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cicaloni V., Costanti F., Pasqui A., Bianchini M., Niccolai N., Bongini P. A bioinformatics approach to investigate structural and non-structural proteins in human coronaviruses. Front. Genet. 2022;13 doi: 10.3389/fgene.2022.891418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2022.891418</ArticleId><ArticleId IdType="pmc">PMC9237418</ArticleId><ArticleId IdType="pubmed">35774504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapikian A.Z. The coronaviruses. Dev. Biol. Stand. 1975;28:42–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">1092577</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappelletti G., Colombrita C., Limanaqi F., Invernizzi S., Garziano M., Vanetti C., Moscheni C., Santangelo S., Zecchini S., Trabattoni D., et al. Human motor neurons derived from induced pluripotent stem cells are susceptible to SARS-CoV-2 infection. Front. Cell. Neurosci. 2023;17 doi: 10.3389/fncel.2023.1285836.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2023.1285836</ArticleId><ArticleId IdType="pmc">PMC10728732</ArticleId><ArticleId IdType="pubmed">38116398</ArticleId></ArticleIdList></Reference><Reference><Citation>Koralnik I.J., Tyler K.L. Covid ‐19: a global threat to the nervous system. Ann. Neurol. 2020;88:1–11. doi: 10.1002/ana.25807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25807</ArticleId><ArticleId IdType="pmc">PMC7300753</ArticleId><ArticleId IdType="pubmed">32506549</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, China. JAMA Neurol. 2020;77:683. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray S.M., Ansari A.M., Frater J., Klenerman P., Dunachie S., Barnes E., Ogbe A. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. Nat. Rev. Immunol. 2023;23:304–316. doi: 10.1038/s41577-022-00809-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00809-x</ArticleId><ArticleId IdType="pmc">PMC9765363</ArticleId><ArticleId IdType="pubmed">36539527</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Wang Y., Kang L., Hu Y., Wang L., Zhong J., Chen H., Ren L., Gu X., Wang G., et al. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg. Microb. Infect. 2021;10:664–676. doi: 10.1080/22221751.2021.1905488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1905488</ArticleId><ArticleId IdType="pmc">PMC8023607</ArticleId><ArticleId IdType="pubmed">33734013</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos L.M., Bruyndonckx R., Zuithoff N.P.A., Little P., Oosterheert J.J., Broekhuizen B.D.L., Lammens C., Loens K., Viveen M., Butler C.C., et al. Lower respiratory tract infection in the community: associations between viral aetiology and illness course. Clin. Microbiol. Infect. 2021;27:96–104. doi: 10.1016/j.cmi.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7118666</ArticleId><ArticleId IdType="pubmed">32244051</ArticleId></ArticleIdList></Reference><Reference><Citation>Garziano M., Utyro O., Poliseno M., Santantonio T.A., Saulle I., Strizzi S., Lo Caputo S., Clerici M., Introini A., Biasin M. Natural SARS-CoV-2 infection affects neutralizing activity in saliva of vaccinees. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.820250.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.820250</ArticleId><ArticleId IdType="pmc">PMC8962193</ArticleId><ArticleId IdType="pubmed">35359971</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhlebach M.S., Zorn B.T., Esther C.R., Hatch J.E., Murray C.P., Turkovic L., Ranganathan S.C., Boucher R.C., Stick S.M., Wolfgang M.C. Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children. PLoS Pathog. 2018;14 doi: 10.1371/journal.ppat.1006798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006798</ArticleId><ArticleId IdType="pmc">PMC5773228</ArticleId><ArticleId IdType="pubmed">29346420</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H., Matsuoka M., Freire M. Oral mucosa immunity: ultimate strategy to stop spreading of pandemic viruses. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1220610.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1220610</ArticleId><ArticleId IdType="pmc">PMC10622784</ArticleId><ArticleId IdType="pubmed">37928529</ArticleId></ArticleIdList></Reference><Reference><Citation>Garziano M., Utyro O., Strizzi S., Vanetti C., Saulle I., Conforti C., Cicilano F., Ardizzone F., Cappelletti G., Clerici M., et al. Saliva and plasma neutralizing activity induced by the administration of a third bnt162b2 vaccine dose. Int. J. Mol. Sci. 2022;23 doi: 10.3390/ijms232214341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232214341</ArticleId><ArticleId IdType="pmc">PMC9693379</ArticleId><ArticleId IdType="pubmed">36430815</ArticleId></ArticleIdList></Reference><Reference><Citation>Edridge A.W.D., Kaczorowska J., Hoste A.C.R., Bakker M., Klein M., Loens K., Jebbink M.F., Matser A., Kinsella C.M., Rueda P., et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med. 2020;26:1691–1693. doi: 10.1038/s41591-020-1083-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Tawfiq J.A., Rabaan A.A., Al-Omari A., Al Mutair A., Al-Qahtani M., Tirupathi R. Learning from SARS and MERS: COVID-19 reinfection where do we stand? Trav. Med. Infect. Dis. 2021;41 doi: 10.1016/j.tmaid.2021.102024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102024</ArticleId><ArticleId IdType="pmc">PMC7962586</ArticleId><ArticleId IdType="pubmed">33741499</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav R., Chaudhary J.K., Jain N., Chaudhary P.K., Khanra S., Dhamija P., Sharma A., Kumar A., Handu S. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells. 2021;10:821. doi: 10.3390/cells10040821.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040821</ArticleId><ArticleId IdType="pmc">PMC8067447</ArticleId><ArticleId IdType="pubmed">33917481</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagliani R., Forni D., Clerici M., Sironi M. Coding potential and sequence conservation of SARS-CoV-2 and related animal viruses. Infect. Genet. Evol. 2020;83 doi: 10.1016/j.meegid.2020.104353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104353</ArticleId><ArticleId IdType="pmc">PMC7199688</ArticleId><ArticleId IdType="pubmed">32387562</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Tian J., Zhang Q., Xie Y., Wang K., Qiu S., Lu K., Liu Y. Comparing the nucleocapsid proteins of human coronaviruses: structure, immunoregulation, vaccine, and targeted drug. Front. Mol. Biosci. 2022;9 doi: 10.3389/fmolb.2022.761173.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2022.761173</ArticleId><ArticleId IdType="pmc">PMC9099148</ArticleId><ArticleId IdType="pubmed">35573742</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi M., Hasnain S.E., Rosenthal B., Phan T., Luciani F., Shaw M.-A., Sallum M.A., Mirhashemi M.E., Morand S., González-Candelas F. SARS-CoV-2 and COVID-19: a genetic, epidemiological, and evolutionary perspective. Infect. Genet. Evol. 2020;84 doi: 10.1016/j.meegid.2020.104384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104384</ArticleId><ArticleId IdType="pmc">PMC7256558</ArticleId><ArticleId IdType="pubmed">32473976</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccaluga P.P., Malerba G., Navari M., Diani E., Concia E., Gibellini D. Cross-immunization against respiratory coronaviruses may protect children from SARS-CoV2: more than a simple hypothesis? Front Pediatr. 2021;8 doi: 10.3389/fped.2020.595539.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2020.595539</ArticleId><ArticleId IdType="pmc">PMC7849449</ArticleId><ArticleId IdType="pubmed">33537261</ArticleId></ArticleIdList></Reference><Reference><Citation>Loyal L., Braun J., Henze L., Kruse B., Dingeldey M., Reimer U., Kern F., Schwarz T., Mangold M., Unger C., et al. Cross-reactive CD4 + T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science. 2021;374 doi: 10.1126/science.abh1823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1823</ArticleId><ArticleId IdType="pmc">PMC10026850</ArticleId><ArticleId IdType="pubmed">34465633</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni M., Migliori E., Fu J., Assal A., Chan H.T., Pan J., Khatiwada P., Ciubotariu R., May M.S., Pereira M., et al. The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses. Immunology. 2023 doi: 10.1101/2023.01.03.519511. [preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.03.519511</ArticleId><ArticleId IdType="pmc">PMC10612330</ArticleId><ArticleId IdType="pubmed">37901229</ArticleId></ArticleIdList></Reference><Reference><Citation>Saletti G., Gerlach T., Jansen J.M., Molle A., Elbahesh H., Ludlow M., Li W., Bosch B.-J., Osterhaus A.D.M.E., Rimmelzwaan G.F. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Sci. Rep. 2020;10 doi: 10.1038/s41598-020-78506-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78506-9</ArticleId><ArticleId IdType="pmc">PMC7722724</ArticleId><ArticleId IdType="pubmed">33293664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mileto D., Fenizia C., Cutrera M., Gagliardi G., Gigantiello A., De Silvestri A., Rizzo A., Mancon A., Bianchi M., De Poli F., et al. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. Emerg. Microb. Infect. 2021;10:2235–2243. doi: 10.1080/22221751.2021.2004866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2004866</ArticleId><ArticleId IdType="pmc">PMC8648019</ArticleId><ArticleId IdType="pubmed">34749573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N., Barouch D.H. SARS-CoV-2 hybrid immunity: the best of both worlds. J. Infect. Dis. 2023;228:1311–1313. doi: 10.1093/infdis/jiad353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad353</ArticleId><ArticleId IdType="pubmed">37592872</ArticleId></ArticleIdList></Reference><Reference><Citation>Beitari S., Duque D., Bavananthasivam J., Hewitt M., Sandhu J.K., Hadžisejdić I., Tran A. Cross protection to SARS-CoV-2 variants in hamsters with naturally-acquired immunity. Virol. J. 2023;20:167. doi: 10.1186/s12985-023-02136-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02136-6</ArticleId><ArticleId IdType="pmc">PMC10386765</ArticleId><ArticleId IdType="pubmed">37507719</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano E., Paciello I., Piccini G., Manganaro N., Pileri P., Hyseni I., Leonardi M., Pantano E., Abbiento V., Benincasa L., et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature. 2021;600:530–535. doi: 10.1038/s41586-021-04117-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04117-7</ArticleId><ArticleId IdType="pmc">PMC8674140</ArticleId><ArticleId IdType="pubmed">34670266</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E.M., Li S.H., Awofolaju M., Eilola T., Goodwin E., Bolton M.J., Gouma S., Manzoni T.B., Hicks P., Goel R.R., et al. SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. Cell Rep. 2022;41 doi: 10.1016/j.celrep.2022.111496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111496</ArticleId><ArticleId IdType="pmc">PMC9578169</ArticleId><ArticleId IdType="pubmed">36261003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann D. The role of the oral cavity in SARS-CoV-2- and other viral infections. Clin Oral Investig. 2023;27:15–22. doi: 10.1007/s00784-023-05078-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00784-023-05078-z</ArticleId><ArticleId IdType="pmc">PMC10262116</ArticleId><ArticleId IdType="pubmed">37310513</ArticleId></ArticleIdList></Reference><Reference><Citation>Fábián T.K., Hermann P., Beck A., Fejérdy P., Fábián G. Salivary defense proteins: their network and role in innate and acquired oral immunity. Int. J. Mol. Sci. 2012;13:4295–4320. doi: 10.3390/ijms13044295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms13044295</ArticleId><ArticleId IdType="pmc">PMC3344215</ArticleId><ArticleId IdType="pubmed">22605979</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.J.A., Ribeiro L.R., Lima K.V.B., Lima L.N.G.C. Adaptive immunity to SARS-CoV-2 infection: a systematic review. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.1001198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1001198</ArticleId><ArticleId IdType="pmc">PMC9589156</ArticleId><ArticleId IdType="pubmed">36300105</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S. Pathogen recognition by innate immunity and its signaling. Proc Jpn Acad Ser B. 2009;85:143–156. doi: 10.2183/pjab.85.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.2183/pjab.85.143</ArticleId><ArticleId IdType="pmc">PMC3524297</ArticleId><ArticleId IdType="pubmed">19367086</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.C.S., Owen C.J., Tham C.Y.L., Bertoletti A., Van Dorp L., Balloux F. Pre-existing T cell-mediated cross-reactivity to SARS-CoV-2 cannot solely be explained by prior exposure to endemic human coronaviruses. Infect. Genet. Evol. 2021;95 doi: 10.1016/j.meegid.2021.105075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.105075</ArticleId><ArticleId IdType="pmc">PMC8428999</ArticleId><ArticleId IdType="pubmed">34509646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Wang J., Sun P., Qin J., Yang X., Chen D., Zhang Y., Zhong N., Wang Z. SARS-CoV-2 epitope-specific T cells: immunity response feature, TCR repertoire characteristics and cross-reactivity. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1146196.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1146196</ArticleId><ArticleId IdType="pmc">PMC10036809</ArticleId><ArticleId IdType="pubmed">36969254</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobben M., Van Der Straten K., Brouwer P.J., Brinkkemper M., Maisonnasse P., Dereuddre-Bosquet N., Appelman B., Lavell A.A., Van Vught L.A., Burger J.A., et al. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife. 2021;10 doi: 10.7554/eLife.70330.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.70330</ArticleId><ArticleId IdType="pmc">PMC8610423</ArticleId><ArticleId IdType="pubmed">34812143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks J., Klumpp-Thomas C., Kalish H., Shunmugavel A., Mehalko J., Denson J.-P., Snead K.R., Drew M., Corbett K.S., Graham B.S., et al. Serologic cross-reactivity of SARS-CoV-2 with endemic and seasonal betacoronaviruses. J. Clin. Immunol. 2021;41:906–913. doi: 10.1007/s10875-021-00997-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-00997-6</ArticleId><ArticleId IdType="pmc">PMC7962425</ArticleId><ArticleId IdType="pubmed">33725211</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartsch S.M., O'Shea K.J., John D.C., Strych U., Bottazzi M.E., Martinez M.F., Ciciriello A., Chin K.L., Weatherwax C., Velmurugan K., et al. The potential epidemiologic, clinical, and economic value of a universal coronavirus vaccine: a modelling study. eClinicalMedicine. 2024 doi: 10.1016/j.eclinm.2023.102369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102369</ArticleId><ArticleId IdType="pmc">PMC10965405</ArticleId><ArticleId IdType="pubmed">38545093</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj V., Gadi N., Spihlman A.P., Wu S.C., Choi C.H., Moulton V.R. Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections? Front. Physiol. 2021;11 doi: 10.3389/fphys.2020.571416.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2020.571416</ArticleId><ArticleId IdType="pmc">PMC7835928</ArticleId><ArticleId IdType="pubmed">33510644</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin E., Choe Y.J., Ryu B., Kim N.-Y., Lee H.J., Kim D.H., Kim S.-S., Kwon D., Yun K.W., Park S.E., et al. Pediatric deaths associated with coronavirus disease 2019 (COVID-19) in korea. J. Kor. Med. Sci. 2023;38:e21. doi: 10.3346/jkms.2023.38.e21.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e21</ArticleId><ArticleId IdType="pmc">PMC9842489</ArticleId><ArticleId IdType="pubmed">36647219</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>